Welcome to our dedicated page for Heico SEC filings (Ticker: HEI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking every engineering change, aftermarket part sale, and defense contract that moves Heico Corporation’s numbers can feel like chasing parts across a global supply chain. Aerospace disclosures often hide key data—flight-support margins, satellite electronics backlogs—deep inside 300-page reports. That’s why investors searching “How to read Heico’s 10-K annual report” or “Heico insider trading Form 4 transactions” land here.
Stock Titan’s AI turns raw EDGAR filings into clear takeaways. Open any 10-Q and our engine highlights segment revenue so you instantly grasp trends in the Flight Support Group. Need “Heico quarterly earnings report 10-Q filing” context? One click shows quarter-over-quarter spare-parts growth. Curious about “Heico 8-K material events explained”? We flag contract wins and acquisition announcements minutes after they post. Real-time alerts surface “Heico Form 4 insider transactions” so you can monitor executive stock moves before the market reacts. Even the dense proxy is decoded—search “Heico proxy statement executive compensation” and see bullet-point pay tables without sifting through legalese.
Every filing type is here, updated the moment EDGAR releases it:
- 10-K – “Heico annual report 10-K simplified” lists risk factors tied to airline cycles.
- 10-Q – “Heico earnings report filing analysis” with AI commentary on backlog shifts.
- 8-K – Immediate summaries of material events and contract awards.
- Form 4 – “Heico executive stock transactions Form 4” timeline in real time.
Stop downloading PDFs and start “understanding Heico SEC documents with AI.” Whether you compare avionics segment margins or scan “Heico insider trading Form 4 transactions,” our platform keeps you informed, fast, and confident.
HEICO Corp. (symbol HEI) has filed a Form 144 indicating the planned sale of insider-owned shares.
- Amount for sale: 60,000 shares of Class A common stock.
- Estimated market value: US$19.296 million (based on the market price at the time the form was prepared).
- % of shares outstanding: roughly 0.11% of the 55,048,774 shares reported outstanding.
- Broker: Raymond James & Associates, St. Petersburg, FL.
- Planned sale date: on or about 15 July 2025 via the NYSE.
- Original acquisition: the securities were purchased on 5 June 1989 for cash in open-market transactions; no indication that they were gifts or part of a compensation plan.
- Recent activity: the filer reports no other sales of the issuer’s securities during the past three months.
The filing is a routine notice required under Rule 144 and does not itself consummate a transaction; it simply affords the insider a 90-day window to execute the sale, subject to volume and manner-of-sale limitations.
Form 4 filing overview: Abbott Laboratories (ABT) Executive Vice President Louis H. Morrone reported one transaction dated 30 June 2025.
- Transaction code: F (as reported in the form).
- Shares affected: 269 common shares without par value.
- Transaction price: $134.38 per share.
- Post-transaction direct holdings: 66,609 common shares.
- Indirect holdings: 12 common shares held in the Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) as of 30 June 2025.
There were no derivative security transactions reported and no indication of additional purchases, option exercises, or sales beyond the single Code F entry. Morrone remains an insider with substantial equity exposure to Abbott Laboratories after the reported withholding.